A Study of Interviews to Evaluate the Content Validity of Patient- Reported Outcomes for Use in Myelodysplastic Syndromes (MDS)

Overview

Información sobre este estudio

The primary objective of this study is to generate evidence for the content validity of the Functional Assessment of Cancer Therapy - Anemia (FACT-An) and the Quality of Life in Myelodysplasia Scale (QUALMS) for use in an MDS population. Specifically, the study aims to gain an understanding of the experience of patients with MDS, including the key symptoms and impacts, as well as assess the patient understanding and relevance of the FACT-An and QUALMS for use in patients with MDS such that they may be used as trial endpoints.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Subjects eligible for enrolment in the study must meet all of the following criteria:

  1. Male or female ≥18 years of age
  2. Diagnosis of MDS according to World Health Organisation (WHO) criteria confirmed by bone marrow aspirate and biopsy
  3. International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk MDS
  4. Red Blood Cell (RBC) transfusion dependent (i.e. requiring at least 4 units during an 8-week period)
  5. Has MDS that is relapsed/refractory to erythropoietic stimulating agent (ESA) treatment
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 2
  7. Able to attend and participate in a 90 minute interview. Must be literate in US-English and verbally fluent in US-English

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  1. Subject has received an investigational drug or used an invasive investigational medical device within 30 days prior to screening or is currently enrolled in an investigational study;
  2. Prior history of hematopoietic stem cell transplant;
  3. Diagnosed or treated for malignancy other than MDS;
  4. Significant difficulty hearing, reading or speaking;
  5. Has an uncontrolled psychiatric condition (e.g., schizophrenia, bipolar disorder) or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study or likely to have difficulty participating in a 90 minute interview;
  6. Has severe physical, neurological or cognitive deficits that might affect their ability to participate in an interview about their experience of MDS and completion of two questionnaires.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Mrinal Patnaik, M.B.B.S.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20396301

Mayo Clinic Footer